Skip to content
Triangle logo TriangleGet started
← Full study record

NCT07217119 · OUTCOME

DE Phase: Titer of ADAs Against Belantamab Mafodotin

Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM · Source last updated 2026-06-25

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Titer
Interval / dispersion
Full Range
Time frame
Up to approximately 281 weeks

What was measured

Serum samples were collected for the analysis of the presence of ADAs using validated immunoassays. All samples were tested in screening assay, and positive samples were further characterized for antibody titers.

Analysis population: Safety population. Only those participants with positive post-baseline antibody against belantamab mafodotin were analyzed.

Groups in this outcome

1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab

Participants with Relapsed/Refractory Multiple Myeloma (RRMM) received 1.9 milligram (mg)/kilogram (kg) of belantamab mafodotin intravenous (IV) infusion in combination with 8 mg feladilimab IV infusion, given 1 hour after belantamab mafodotin end of infusion (EOI), once every 3 weeks (Q3W).

2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab

Participants with RRMM received 2.5 mg/kg belantamab mafodotin IV infusion in combination with 8 mg feladilimab IV infusion, given 1 hour after belantamab mafodotin EOI Q3W.

2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab

Participants with RRMM received 2.5 mg/kg belantamab mafodotin IV infusion in combination with 24 mg feladilimab IV infusion, given 1 hour after belantamab mafodotin EOI Q3W.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab0
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab1
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab0

Reported measurements

Source class 1
Values in Titer · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab100Not reportedNANAFull range is not applicable as only a single participant was analyzed. Median value presented here is the actual titer value for this single participant.
Complete source fields
classes
  1. categories
    1. measurements
      1. comment
        Full range is not applicable as only a single participant was analyzed. Median value presented here is the actual titer value for this single participant.
        group Id
        OG001
        lower Limit
        NA
        upper Limit
        NA
        value
        100
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    2. group Id
      OG001
      value
      1
    3. group Id
      OG002
      value
      0
    units
    Participants
description
Serum samples were collected for the analysis of the presence of ADAs using validated immunoassays. All samples were tested in screening assay, and positive samples were further characterized for antibody titers.
dispersion Type
Full Range
groups
  1. description
    Participants with Relapsed/Refractory Multiple Myeloma (RRMM) received 1.9 milligram (mg)/kilogram (kg) of belantamab mafodotin intravenous (IV) infusion in combination with 8 mg feladilimab IV infusion, given 1 hour after belantamab mafodotin end of infusion (EOI), once every 3 weeks (Q3W).
    id
    OG000
    title
    1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab
  2. description
    Participants with RRMM received 2.5 mg/kg belantamab mafodotin IV infusion in combination with 8 mg feladilimab IV infusion, given 1 hour after belantamab mafodotin EOI Q3W.
    id
    OG001
    title
    2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab
  3. description
    Participants with RRMM received 2.5 mg/kg belantamab mafodotin IV infusion in combination with 24 mg feladilimab IV infusion, given 1 hour after belantamab mafodotin EOI Q3W.
    id
    OG002
    title
    2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab
param Type
MEDIAN
population Description
Safety population. Only those participants with positive post-baseline antibody against belantamab mafodotin were analyzed.
reporting Status
POSTED
time Frame
Up to approximately 281 weeks
title
DE Phase: Titer of ADAs Against Belantamab Mafodotin
type
SECONDARY
unit Of Measure
Titer

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice